The conventional advice on AI adoption in pharmaceutical organizations is to start at the top: secure executive sponsorship, build an enterprise strategy, and deploy from the C-suite down. Based on what we have observed across real deployments, this approach consistently produces resistance, low utilization, and failed initiatives.
The reason is straightforward. Leadership rarely knows the actual pain points faced by QA analysts, regulatory writers, and validation engineers doing the daily work. And in an industry saturated with headlines about AI replacing jobs, nobody is motivated to train their own replacement. Top-down deployment without grassroots buy-in produces tools that sit unused, which means no time saved, no ROI, and no organizational learning.
This session presents a bottom-up framework for AI readiness in regulated life sciences organizations. It covers four dimensions: data quality and availability, use case selection, governance infrastructure, and people and buy-in. Attendees will learn how to identify real problems that frontline staff actually want solved, why starting with a simple and imperfect solution outperforms waiting for a comprehensive one, and how to build organizational AI maturity from the bench level upward. Upper management support is necessary, but it must be anchored to problems people actually need fixed.
Attendees leave with a scored readiness self-assessment they can use in their next internal planning conversation.